82759
document
Gastric ulcer treatment with intravenous human epidermal growth factor : a double-blind controlled clinical study . We introduced a double-blind controlled clinical study to compare intravenous human epidermal growth factor ( hEGF ) to cetraxate hydrochloride ( CH ) , an antiulcer drug , for their healing effect on gastric ulcers . We also prospected an oral use of EGF on the basis of our experimental evidence . In the clinical trial , the rate of ulcer healing within 8 weeks was 77.9 % ( 67/86 ) in patients receiving 6 micrograms EGF intravenously twice a week , being significantly greater than 51.7 % ( 45/87 ) in those given CH . Taking together all aspects assessed including the healing rate , pain relief , blood examination and adverse reactions , we judged the hEGF to be a useful and safe anticuler drug . In rats , 50 micrograms/kg mouse EGF ( mEGF ) and 2 % hydroxypropyl cellulose ( HPC ) or 1.0 g/kg sucralfate given by gastric intubation significantly raised the residual mEGF levels in both gastric luminal content ( HPC : x 30 ; sucralfate : x 300 as high as those in EGF alone ) and tissue ( HPC : x 60 ; sucralfate : x 100 ) . In addition , the combined treatments significantly promoted healing of rat gastric ulcers whereas each agent alone had no significant effect as compared with control ( saline ) . This indicated the beneficial effect on ulcers of oral administration of EGF with agents allowing it to remain at high levels in the stomach , whereas most reports suggested less effect of oral EGF on healing of gastroduodenal ulcers . Subsequent to the clinical study , evaluation of oral use of EGF may be expected as the next step in the treatment of ulcers . The experimental evidence above would possibly be a guide for such trial .
82760
Intervention_Pharmacological
human epidermal growth factor
82761
Intervention_Pharmacological
intravenous human epidermal growth factor ( hEGF )
82762
Intervention_Pharmacological
cetraxate hydrochloride ( CH )
82763
Intervention_Pharmacological
EGF
82764
Intervention_Pharmacological
EGF
82765
Intervention_Pharmacological
CH
82766
Intervention_Pharmacological
hEGF
82767
Intervention_Pharmacological
hydroxypropyl cellulose
82768
Intervention_Pharmacological
EGF
82769
Intervention_Pharmacological
EGF
82770
Outcome_Physical
gastric ulcers
82771
Outcome_Physical
rate of ulcer healing
82772
Outcome_Physical
healing rate
82773
Outcome_Pain
pain relief
82774
Outcome_Physical
blood examination
82775
Outcome_Adverse-effects
adverse reactions
82776
Outcome_Physical
residual mEGF levels
82777
Outcome_Physical
healing of rat gastric ulcers
82778
Participant_Condition
Gastric ulcer
82779
Participant_Sample-size
67/86
82780
Participant_Condition
gastric ulcers